Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CISD1 | Q9NZ45 | 4/20 | 0.59 |
| ▸ | MAOA | P21397 | 3/20 | 0.54 |
| ▸ | MAOB | P27338 | 3/20 | 0.54 |
| ▸ | PIM1 | P11309 | 7/20 | 0.54 |
| ▸ | PIM2 | Q9P1W9 | 6/20 | 0.54 |
| ▸ | IGF1R | P08069 | 2/20 | 0.52 |
| ▸ | TTR | P02766 | 1/20 | 0.51 |
| ▸ | INSR | P06213 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.48 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6074056 | 1.00 | CISD1 (0.59) | CISD1MAOAMAOBPIM1PIM2 | |
| SCHEMBL6074372 | 0.85 | PIM1 (0.54) | CISD1MAOAMAOBPIM1PIM2 | |
| SCHEMBL6074371 | 0.85 | PIM1 (0.54) | CISD1MAOAMAOBPIM1PIM2 | |
| SCHEMBL6074172 | 0.83 | CISD1 (0.54) | CISD1MAOAMAOBPIM1PIM2 | |
| SCHEMBL6074177 | 0.83 | CISD1 (0.54) | CISD1MAOAMAOBPIM1PIM2 | |
| SCHEMBL6074055 | 0.80 | PIM1 (0.57) | CISD1MAOAMAOBPIM1PIM2 | |
| SCHEMBL6074052 | 0.80 | PIM1 (0.57) | CISD1MAOAMAOBPIM1PIM2 | |
| SCHEMBL7247851 | 0.78 | CISD1 (0.48) | CISD1MAOAMAOBPIM1PIM2 | |
| SCHEMBL1247700 | 0.78 | CISD1 (0.75) | CISD1MAOAMAOBPIM1PIM2 | |
| SCHEMBL1247698 | 0.78 | CISD1 (0.75) | CISD1MAOAMAOBPIM1PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7022716-B2 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | WYETH (US) | 2006-04-04 | — | — | US | disclosed |
| US-20030144326-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | WYETH | 2003-07-31 | — | — | US | disclosed |
| EP-1301482-A1 | CYCLIC AMINE PHENYL BETA-3 ADRENERGIC RECEPTOR AGONISTS | Wyeth (US) | 2003-04-16 | — | — | EP | disclosed |
| US-6525202-B2 | E.g., substituted (4-amino-5-hydroxyphenyl)-oxy-)piperidinyl thiazolidin-2,4-dione; antidiabetic agents; atherosclerosis, gastrointestinal, metabolic disorders, glaucoma, neurogenetic inflammation, ocular hypertension and frequent urination | WYETH | 2003-02-25 | — | — | US | disclosed |
| US-20020028835-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | WYETH | 2002-03-07 | — | — | US | disclosed |
| WO-2002006232-A1 | CYCLIC AMINE PHENYL BETA-3 ADRENERGIC RECEPTOR AGONISTS | WYETH (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144326-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | ADRB1, ADRB3, ADRB2 | CISD1 3821/4885MAOA 1270/4885MAOB 786/4885 |
| US-20020028835-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | ADRB1, ADRB3, ADRB2 | CISD1 3821/4885MAOA 1270/4885MAOB 786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.